Thyroid Gland Medullary Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Thyroid Gland Carcinoma (359)

Thyroid Gland Anaplastic Carcinoma (70)

Thyroid Gland Papillary Carcinoma (58)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Hurthle Cell Carcinoma (12)

Thyroid Gland Carcinoma (359)

Thyroid Gland Anaplastic Carcinoma (70)

Thyroid Gland Papillary Carcinoma (58)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Hurthle Cell Carcinoma (12)

›

No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
TMB-H	Thyroid Gland Medullary Carcinoma	TMB-H	Thyroid Gland Medullary Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
RAS mutation	Thyroid Gland Medullary Carcinoma	RAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
KRAS mutation	Thyroid Gland Medullary Carcinoma	KRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
NRAS mutation	Thyroid Gland Medullary Carcinoma	NRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
KRAS mutation	Thyroid Gland Medullary Carcinoma	KRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	SY-5007 Sensitive: C2 – Inclusion Criteria SY-5007 Sensitive : C2	SY-5007 Sensitive: C2 – Inclusion Criteria SY-5007 Sensitive : C2
RET V804*	Thyroid Gland Medullary Carcinoma	RET V804*	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET C634*	Thyroid Gland Medullary Carcinoma	RET C634*	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET C634R	Thyroid Gland Medullary Carcinoma	RET C634R	Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
RET V804M	Thyroid Gland Medullary Carcinoma	RET V804M	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3
RET V804L	Thyroid Gland Medullary Carcinoma	RET V804L	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3
RET positive	Thyroid Gland Medullary Carcinoma	RET positive	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	EP0031 Sensitive: C3 – Early Trials EP0031 Sensitive : C3	EP0031 Sensitive: C3 – Early Trials EP0031 Sensitive : C3
RET V804M + RET M918T + RET G810 + RET Y806	Thyroid Gland Medullary Carcinoma	RET V804M + RET M918T + RET G810 + RET Y806	Thyroid Gland Medullary Carcinoma	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4
NF1 mutation	Thyroid Gland Medullary Carcinoma	NF1 mutation	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
RET M918T + ATM L804fs4 + ATM S978fs12	Thyroid Gland Medullary Carcinoma	RET M918T + ATM L804fs4 + ATM S978fs12	Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
ATM S978fs*12	Thyroid Gland Medullary Carcinoma	ATM S978fs*12	Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
ATM L804fs*4	Thyroid Gland Medullary Carcinoma	ATM L804fs*4	Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4

Thyroid Gland Medullary Carcinoma

Associations(61)

Associations
(61)